Cheetah Medical, a Newton Center, MA-based provider of non-invasive hemodynamic monitoring, closed a $9m round of funding.
The round was by Fletcher Spaght Ventures, with participation from Springfield Investment Management, MVM Life Science Partners, Robert Bosch Venture Capital and Ascension Health Ventures.
The company intends to use the funds for the expansion of its sales and marketing activities in the U.S. and internationally.
Led by Stephen Reeders and Chris Hutchison, President and CEO, Chairman, Cheetah Medical manufactures a management system, which offers a non-invasive means to measure key hemodynamic parameters based on its proprietary bioreactance technology.
It is available in more than 60 countries.